This document is a quick and concise evidence-based summary to provide additional information, instruction, or guidance to complement a treatment protocol or clinical resource document.
Initial risk stratification for clinically localised prostate adenocarcinoma.
| Risk group |
Clinical/pathological features |
| Very low* |
Has all of the following:
- T1c
- Grade Group 1
- PSA <10 ng/ml
- Fewer than 3 prostate biopsy fragments/cores positive, ≤50% cancer in each fragmentation
- PSA density <0.15 ng/ml/g.
|
| Low* |
Has all of the following but does not qualify for very low risk:
- T1-T2a
- Grade Group 1
- PSA <10 ng/ml.
|
| Intermediate |
Has all of the following:
- No high risk group features
- No very high risk group features
- Has one or more intermediate risk factors (IRF):
- T2b-T2c, OR
- Grade Group 2 or 3, OR
- PSA 10-20 ng/ml.
|
Favourable intermediate |
Has all of the following:
- 1 IRF
- Grade Group 1 or 2
- <50% biopsy cores positive.
|
| Unfavourable intermediate |
Has one or more of the following:
- 2 or 3 IRFs
- Grade Group 3
- ≥50% biopsy cores positive.
|
| High^ |
Has no very high risk features and at least one high risk feature:
- T3a, OR
- Grade Group 4 or 5, OR
- PSA >20 ng/ml.
|
| Very high^ |
Has at least one of the following:
- T3b-T4, OR
- Primary Gleason pattern 5, OR
- 2 or 3 high risk features, OR
- >4 cores with Grade Group 4 or 5.
|
Adapted from NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) - Prostate Cancer, Version 2.2020 - May 21, 2020.r
* Very low and low risk are considered 'low risk' in the context of eviQ prostate adenocarcinoma definitive EBRT protocols.
^ High and very high risk are considered 'high risk' in the context of eviQ prostate adenocarcinoma definitive EBRT protocols.
While every effort has been made to ensure the accuracy of the content at the time of publication, the Cancer Institute NSW does not accept any liability, with respect to loss, damage, injury or expense arising from any such errors or omission in the contents of this work. Any reference to specific companies or products as examples does not imply endorsement. . While eviQ endeavours to link to reliable sources that provide accurate information, eviQ and the Cancer Institute NSW do not endorse or accept responsibility for the accuracy, currency, reliability or correctness of the content of linked external information source. Use is subject to eviQ’s disclaimer available at www.eviQ.org.au
Send feedback for this page
- First approved:
-
- Last reviewed:
-
- Review due:
-
The currency of this information is guaranteed only up until the date of printing, for any updates please check:
https://www.eviq.org.au/p/3417
19 Apr 2024